Nuclea Biotechnologies Inc. is teaming up with Boston Medical Center to research breast and prostate cancer.
The Pittsfield, Mass.-based subsidiary of Nuclea Biotherapies LLC entered into a three-year deal to support research at BMC for the development of personalized cancer treatments.
As part of the agreement, Nuclea will pay the hospital $1.4 million over the project’s duration and have the right of first refusal for commercialization on discoveries made during the collaboration, according to the company.
The research, lead by BMC’s Departments of Pathology and Radiology, will focus on the genetic make-up of specific tumors with the end goal of advancing the diagnostic tools that doctors use to identify biomarkers present in patients afflicted with breast and prostate cancers.
"This is a great step forward for Nuclea, BMC, and the biotechnology industry. The continued advancement of biomarker research and a focus on personalized medicine will help save lives and reduce costly, ineffective treatments," Nuclea CEO Patrick Muraca said in prepared remarks.
Nuclea won a $733,000 federal grant through the Qualifying Therapeutic Discovery Project to grow its staff at its Pittsfield genomics center in November.